semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Traumatic Brain Injury Fatigue Moderate or severe TBI (assessed by a Glasgow Coma Scale between 3-13 within the first 24 hours post-injury, and a radiologically confirmed intracranial injury) Patients from the Eastern part of Norway  Pre or comorbid neurological, medical or severe psychological disorders with the potential to cause fatigue Ongoing substance abuse Cognitive or physical impairments to such a degree that neuropsychological assessment and self-report measures cannot be adequately applied
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thrombosis age > 18 years All patients diagnosed as BCR-ABL negative myeloproliferative neoplasm e.g: Polycythemia vera Essential thrombocythemia Primary myelofibrosis  BCR ABL positive MPN e.g CML Secondary erythrocytosis Secondary thrombocytosis Secondary bone marrow fibrosis
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 60.0-75.0,  Kinesio Taping Knee Osteoarthritis • Female subjects aged 60 years and over, non-obese (BMI between 18.5 and 24.9 kg / m2), with diagnosis of knee OA according to the of the American College of Rheumatology (Altman et al. , 1986), which are: knee pain most of the day during the last weeks and age greater than 60 years (mandatory criteria), and at least two of the following stiffness after rest less than 30 minutes, crackle in the affected knee , joint increase of firm consistency, absence of temperature increase and painful hypersensitivity to palpation Individuals with radiographic signs of degeneration of the knee joint Individuals with any degree of degeneration according to the Kellgren-Lawrence scale Individuals with a pain scale above 3 according to NPRS Stiffness in the knee for at least 6 months prior to screening Stiffness during the beginning of activities Intermittent swelling Never have used KT Individuals with no history of associated joint disease or systemic rheumatic disease and / or history of surgery in the affected lower limb Individuals who are not under physiotherapeutic treatment during the intervention  • Individuals who report pain during the procedure Individuals who do not complete the treatment time or who do not perform the evaluation procedures correctly, making it impossible to collect any of the data investigated Individuals with allergy to bandage or cutaneous injury in the region where KT will be applied Individuals who present hypertensive peak during the evaluations
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Kidney Disease End Stage Kidney Disease Chronic Kidney Disease Mineral and Bone Disorder Renal Osteodystrophy Secondary Hyperparathyroidism Chronic kidney disease stage 3, 4 or 5 Stable dose of vitamin D for 2-months  Dialysis Current use or treatment in the past one year with oral or inhaled glucocorticoids for more than 90 days Current use or treatment in the past one year with sex hormone/SERM therapy for more than 30 days Any use of bisphosphonates Use of anti-osteoporosis therapies (denosumab, teriparatide, calcitonin or anti-sclerostin antibodies) in last 2 years Any solid organ transplant or bone marrow transplant (Not including skin or cornea) Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy Any cancers within 5-yrs of diagnosis that were metastatic to bone, and that are not in complete remission Any history of leukemia, multiple myeloma, lymphoma, amyloid or paraproteinemias Any congenital or acquired collagen of bone diseases other than osteoporosis or renal osteodystrophy (Including but not limited to: Osteogenesis Imperfecta, X-Linked Hypophosphatemic Rickets, Pagets or Cushings Disease)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Bone Density Increased unrestorable anterior tooth Good oral hygine Adequate bone hieght apical to the alveolus of failing tooth to ensure primary stability   systematic disease which affect osteointgration Bad oral hygiene Broxism, clenching, deep bite, edge to edge and abnormal habits Non-treated peeiodontal diseases Pregnancy and smokers. Severe infection. Loss of labial crest after extraction of failing tooth
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Alveolar Osteitis The are cooperative adult patients able to fulfil the study protocol needing surgical extractions of both lower third molars with similar surgical difficulty according to Pederson scale  The are refuse to participate in the study failure to attend 24, 48, and 72 hours, as well as, 7 days post-surgical appointment visits smokers systemic diseases as diabetes mellitus or being immunosuppressed patients who take local or systemic antibiotics less than 3 months ago, anti-inflammatory or anticoagulant medication in the previous 4 weeks patients who require antibiotic prophylaxis pregnant or breastfeeding women patients with chronic periodontitis in active phase or
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-60.0,  Osteoarthritis Group 1 Meets ACR for OA Kellgren-Lawrence grade 2-3 on knee radiograph Neutral alignment Single symptomatic joint Aged 40-60 years old Ambulatory and in good general health Knee able to fit inside in-vivo knee coil (approx. 18 cm diameter) Group 2 No current symptoms of knee pain or stiffness or other clinical features of OA Aged 40-60 years old Written consent to participate in the study  for both groups History of ipsilateral lower limb fracture History of ipsilateral lower limb surgery (including arthroscopy) Metabolic bone disease Inflammatory arthritis Haematological malignancy Paget's disease Bone metastases Contraindication to MR imaging (e.g. pacemaker, severe claustrophobia) No pregnant patients will be included
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bone Metastases Patients who sign the informed consent form and are willing to complete the study according to the plan; 2. Age 18-80 years old; 3. ECOG score ≤ 2 points; 4. CT shows that the main lesion is considered to be ground glass nodular lung cancer; 5. Preoperative examination CEA <5ng/ul 6. There are no bone related symptoms 7. There is no obvious absolute surgical contraindication for preoperative examination  History of bone related diseases. 2. History of other kinds of cancer
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-110.0,  Quality of Life Parastomal Hernia permanent active sigmoideostomy, transverseostomy, jejunostomi or ileostomy temporary active sigmoideostomy, transverseostomy, jejunostomi or ileostomy  age younger than 18 years stoma closure at follow-up death
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chemotherapy-induced Peripheral Neuropathy Ability to understand and the willingness to sign a written informed consent. History of any type of cancer treated with chemotherapy. Chemotherapy induced peripheral neuropathy (CIPN) due to Cisplatin, carboplatin, and oxaliplatin Taxanes paclitaxel, docetaxel, and cabazitaxel Thalidomide, lenalidomide, and pomalidomide Plant alkaloids, such as vinblastine, vincristine, vinorelbine, and etoposide Epothilones, such as ixabepilone Bortezomib, carfilzomib Eribulin Planning to receive treatment for CIPN with memantine XR and pregabalin. Average daily neuropathic pain intensity > 4 measured by item #5 of BPI-SF (Average daily pain at baseline is the average of pain scores over the last 7 days before enrolling patients in to the study). CIPN > grade 1 as measured by NCI-CTCAE v 4.0. Must be ≥ 3 months beyond completion of chemotherapy. Not planning to receive concurrent chemotherapeutic agents during the study period. Patients with diabetes mellitus, peripheral vascular disease, HIV infection, or a significant degenerative or familial neurologic can be included in the study provided they don't have peripheral neuropathy secondary to above mentioned diseases. Allowable types and amount of prior therapy for neuropathy Patients receiving analgesics for pain associated with CIPN are eligible provided they have taken the same dosage and same medication for at least 2 weeks prior to the study initiation  Any pain other than neuropathic pain of equal or greater severity. Patients with sensory polyneuropathy due to AIDS/HIV, complex regional pain syndrome, and Trigeminal neuralgia. History of suicidal ideation. Patients with a history of non-compliance. Patients who are judged by the investigator to be unable or unlikely to understand the nature, scope, and possible consequences of the study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Acromegaly Muscle Dysfunction Physical Activity Exercise Patients with acromegaly, of both sexes, older than 18 and younger than 65 years, either with active or controlled disease Patients who present clinical stability and who are eligible for the treatment protocol (patients with hormone deficiency will continue on replacement therapy - SILVA et al., 2013) Signature of the Informed Consent Term (TCLE)  Patients with inability to perform the 6MWT, according to ATS criteria Patients who have cognitive impairment by mini mental state examination (MEEN) Abandonment of treatment during the application of the protocol Uncontrolled hypertension (> 180/100 mmHg with medication use) Use of psychotropic drugs Any significant limitations due to osteoarthropathy History of surgery in the previous year with exercise restriction. Não Untreated hypothyroidism or hypocortisolism (HUBBLE et al., 2014) IPAQ with very active classification
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Paget Disease of the Vulva Paget Disease, Extramammary Non-invasive, primary or recurrent vulvar Paget's disease after surgical resection Ability to give informed consent Ability to adhere to the study protocol Patients must have biopsy (< 1year) proven recurrent extra mammary Paget's disease Effective contraception for Women of childbearing potential  Invasive vulvar Paget's Disease Underlying adenocarcinoma Subject to photosensitive disorders / reactions Treatment with Imiquimod / Aldara 5% cream in the last 3 months Photodynamic therapy used to treat MPV lesions in the last 3 months Use of photosensitive agents in the last 3 months Treatment with an experimental drug in the 30 days prior to the start of the study Allergic or hypersensitivity to methyl aminolevulinate or any of the other ingredients of this medication (propyl p-hydroxybenzoate, cetostearyl alcohol, methyl p-hydroxybenzoate) Allergic or hypersensitivity to peanut or soya due to the presence of peanut oil in Metvixia® Patient with Porphyria
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Renal Osteodystrophy Patients with reduced renal function: -≥ 18 years estimated Glomerular Filtration Rate (eGFR) ≤ 20 ml/min/1,73m2 PTH < 150 pg/ml or PTH > 300 pg/ml  ongoing malignancy Allergy towards tetracyclin Pregnancy Control Group: -≥ 18 years eGFR >= 60 ml/min under examination for c prostata Prostatic Specific Antigen (PSA) total <40 µg/l Former kidney disease ionized calcium or PTH outside normal range Known metabolic bone disease treatment with anticoagulants
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Head and Neck Carcinoma Documentation of a head and neck cancer diagnosis as evidenced by tissue biopsy Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed Planned standard of care surgery with curative intent for squamous cell carcinoma Have life expectancy of more than 12 weeks Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 1 Hemoglobin >= 9 gm/dL White blood cell count > 3000/mm^3 Platelet count >= 100,000/mm^3 Serum creatinine =< 1.5 mg/dL Liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and total bilirubin) =< 1.5 times the upper reference range  Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study Allergy to iodine or iodinated materials Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment